BCD-248
/ Biocad
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 04, 2025
FLAMMINGO: An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients with Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov)
- P2 | N=100 | Recruiting | Sponsor: Biocad | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 1
Of
1
Go to page
1